GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
Over the past three years, he has worked within high-performance environments across sports including cricket, football, rugby, and HYROX in the UK
Pre-existing GLP-1 therapy needs documentation and continuation planning
Weight loss tablets are not about replacing healthy habits or offering a shortcut
Contact your insurance provider directly to understand your medication coverage
However, Ozempic is not currently approved to treat alcohol use disorder, and more research is needed before firm conclusions can be made